Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | iC9.CAR-CSPG4 T cells |
Synonyms | |
Therapy Description |
Limited information is currently available on iC9.CAR-CSPG4 T cells, a putative chimeric antigen receptor (CAR) T-cell therapy targeting CSPG4 (Nov 2023). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
iC9.CAR-CSPG4 T cells | Limited information is currently available on iC9.CAR-CSPG4 T cells, a putative chimeric antigen receptor (CAR) T-cell therapy targeting CSPG4 (Nov 2023). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06096038 | Phase Ib/II | iC9.CAR-CSPG4 T cells Cyclophosphamide + Fludarabine | Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC | Recruiting | USA | 0 |